Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 08, 2025 18:24 ET | Source: Bragar Eagel & Squire

REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Replimune Group, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Replimune allegedly overstated the IGNYTE trial’s prospects despite major issues that led the FDA to deem it inadequate and not well-controlled.
September 22, 2025 10:31 ET | Source: Bragar Eagel & Squire

REPLIMUNE FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urges Replimune Group, Inc. Investors to Contact the Firm Regarding Class Action Lawsuit

Replimune allegedly overstated its IGNYTE trial despite flaws later flagged by the FDA, leaving investors misled and damaged when the truth emerged.
September 21, 2025 07:40 ET | Source: Faruqi & Faruqi LLP

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Replimune To Contact Him Directly To Discuss Their Options If...
September 19, 2025 10:11 ET | Source: Bragar Eagel & Squire

REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Replimune Group, Inc. and Encourages Investors to Contact the Firm Before September 22nd

Allegedly, defendants overstated IGNYTE trial prospects despite issues that led the FDA to deem it inadequate, misleading investors and causing losses.
September 18, 2025 09:30 ET | Source: Bernstein Liebhard LLP

REPLIMUNE GROUP, INC. (NASDAQ: REPL) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Replimune Group, Inc. Investors of Upcoming Deadline

Replimune (REPL) Shareholder Lawsuit Filed - Contact Bernstein Liebhard For More Information
September 17, 2025 22:04 ET | Source: Faruqi & Faruqi LLP

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Replimune To Contact Him Directly To Discuss Their Options If you purchased or...
September 17, 2025 18:00 ET | Source: Bragar Eagel & Squire

REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Replimune Group, Inc. and Encourages Investors to Contact the Firm Before September 22nd

Replimune allegedly overstated IGNYTE trial prospects; FDA deemed it inadequate, and investors suffered damages when the truth emerged.
September 15, 2025 07:50 ET | Source: Bragar Eagel & Squire

REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Replimune Group, Inc. and Encourages Investors to Contact the Firm Before September 22nd

The lawsuit alleges Replimune overstated IGNYTE prospects; FDA deemed the trial inadequate, making prior statements false and harming investors.
September 15, 2025 07:00 ET | Source: Bernstein Liebhard LLP

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Replimune Group, Inc. (NASDAQ: REPL)

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Replimune Group, Inc. (NYSE: REPL)
September 12, 2025 16:14 ET | Source: The Rosen Law Firm PA

REPL DEADLINE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Replimune Group, Inc. Investors to Secure Counsel Before Important September 22 Deadline in Securities Class Action First Filed by the Firm – REPL

NEW YORK, Sept. 12, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22,...